AI biotech Fathom raises $47M Series A, renames from Atommap

In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng Xu, a longtime scientific leader at ...